Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Genetic Glitches Linked To Common Childhood Cancer

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Pediatrics / Children's Health;  Genetics;  Cancer / Oncology
Article Date: 19 Aug 2009 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

A multicenter team of childhood cancer researchers has discovered two genetic variations linked to an increased risk for acute lymphoblastic leukemia, or ALL, the most common childhood cancer in the United States.

Because these genetic glitches point to a specific subtype of the disease, identifying them in children who already have leukemia could improve treatment, says University of Florida researcher Meenakshi Devidas, Ph.D., a co-author on the study published online in Nature Genetics. Children with this specific subtype of ALL, known as B-hyperdiploid, tend to respond well to chemotherapy.

"The findings indicated inherited genetic variants contribute to the risk of a child getting ALL and likely contribute to a specific subtype of ALL," said Devidas, a research associate professor in the department of epidemiology and health policy research in the UF College of Medicine and co-director of the Children's Oncology Group Statistics and Data Center at UF. "So far, we have known that patients with this subtype respond well to chemotherapy, but we had no idea why that was."

Led by St. Jude Children's Research Hospital scientist Mary Relling, Pharm.D., the researchers conducted the first genomewide association study to check for genetic variations linked to the common cancer.

"This work indicates that as we approach full sequencing of cancer genomes, we should account for the fact that a gene can be made 'abnormal' via both inherited and acquired defects, and so we should not discount subtle inherited genomic variation as contributing to cancer risk," said Relling, chair of the St. Jude Children's Research Hospital department of pharmaceutical sciences and the paper's senior author. "With projects such as these, our collaboration with members of the Children's Oncology Group, which provided additional cases for genetic analysis, helped strengthen our findings."

To identify these genetic variations, the researchers analyzed the genetic makeup of about 400 children with acute lymphoblastic leukemia. After numerous tests, the researchers discovered two variations in tiny strands of DNA - known as single-nucleotide polymorphisms - that pointed to an increased risk for the disease and were also linked to the B-hyperdiploid subtype.

"If a patient has B-hyperdiploid ALL and has the genetic variation then we can at least project that this patient will do well," Devidas said. "Not that all patients do well, but if they have it the chances are higher."

Nearly one-quarter of children with cancer have ALL, National Cancer Institute statistics show. The disease occurs when abnormal white blood cells flood a person's bone marrow, killing the normal white blood cells needed to fight infections. Because of scientific research, the survival rate for this form of leukemia is around 85 percent, up from 5 percent in the 1960s, according to the National Cancer Institute.

The researchers who collaborated on the study are members of the Children's Oncology Group, the only National Institutes of Health/National Cancer Institute pediatric cancer cooperative group. The group performs clinical trials, collects specimens and performs statistical analysis related to pediatric cancers. UF is one of three institutions with a branch of the COG Statistics and Data Center, where study design, data collection and statistical analysis for COG research occurs.

Source:
April Frawley Birdwell
University of Florida


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Haiti Appeal

Haiti Appeal Image
The severe earthquake that struck Haiti has inflicted damage and devastation on a massive scale. Please donate to the Doctors Without Borders Haiti Appeal.

PLEASE DONATE HERE


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Multiple Myeloma? What Causes Multiple Myeloma?
25 Aug 2009
Multiple myeloma, also known as myeloma or plasma cell myeloma, is cancer of the plasma cells - a kind of white blood cell which is present in the bone marrow. Plasma cells make antibodies called immunoglobulin which help fight off infections...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...